The business is genuinely elite (54% operating margins, 102% ROE, 47.6% revenue growth, $11B FCF, beta of 0.45) and forward valuation is reasonable at 24.6x forward P/E on $47.59 forward EPS (PEG ~1.1). However, the technical setup is poor—declining 50 SMA (-1.3% over 30 days), intraday range of 1.6× ATR with -4.6% round-trip, and volume at 3.08M below the 5M+ conviction threshold. The risk/reward is roughly 1:2 from $1,169.60 (T1 at $1,198 is +2.4% vs -4.7% downside to September 11 low). Sequential EPS is deteriorating (Q4'25: $8.26 → Q1'26: $7.39 → Q2'26: $7.94), net margin compressed 550bps with $3.48B unusual items, and M&A increased debt +38% and intangibles +146%. GLP-1 concentration (40-50% of revenue) is structural fragility given IRA overhang and competitive pipeline (Roche, Pfizer oral GLP-1s). The business quality is too elite for a Sell rating, but the near-term setup argues for trimming and waiting for confirmation.

POSITION STRATEGY: For existing LLY holders: Trim 25–35% of current position to lock in gains and reduce exposure into Q3 earnings and orforglipron binary catalysts. Maintain core position of 65–75% given elite underlying business and intact long-term uptrend.

RISK MANAGEMENT: Hard stop-loss on remaining position: $1,073 (200 SMA) on a closing basis. A break of this level on volume would invalidate the long-term thesis and warrant further reduction.

RE-ENGAGEMENT TRIGGERS: Wait for either: (1) Confirmed close above $1,200 on volume >5M shares, or (2) pullback to $1,073–$1,100 zone with bullish reversal structure (hammer, MACD positive cross, volume expansion).

NEW POSITIONS: Do NOT initiate long position at $1,169. Risk/reward is asymmetric to the downside in the near term. Preferred path: Wait for confirmed breakout above $1,200 on volume or a flush to the 200 SMA for cleaner risk/reward setup.

SHORT SETUP: Tactical short entries on rejection at $1,180–$1,188 with stop above $1,247 (June/July swing high). Target $1,073 (200 SMA). Size small given beta of 0.45 limits velocity and underlying business quality means the floor is structural.

POSITION SIZING: Target weight: half of benchmark (~1.5% if benchmark is 3% in healthcare). Maximum position: 2% of portfolio until technical confirmation. Avoid margin or leveraged exposure given binary catalysts ahead.

The investment plan's Underweight recommendation is anchored in a deteriorating near-term setup: the 50 SMA is declining (-1.3% over 30 days), volume at 3.08M sits well below the 5M conviction threshold, and the R/R from $1,169.60 is asymmetric (T1 +2.4% vs. downside -4.7% to the September 11 low — roughly 1:2, not 3:1). Sequential EPS has rolled over (Q4'25 $8.26 → Q2'26 $7.94), net margins compressed 550bps with $3.48B in unusual items, and M&A leverage (debt +38%, intangibles +146%) layers refinancing risk into a higher-for-longer rate environment. Two binary catalysts loom — Q3 2025 earnings (late October) and the orforglipron FDA decision — making the current entry point unattractive. The action is to trim exposure (25–35% per the plan), not exit outright, because the long-term business remains elite (54% op margins, 102% ROE, 47.6% revenue growth) and the 200 SMA structural uptrend is intact at +8.9%.

Stop loss: $1073.00

Sizing: Trim 25–35% of current LLY position; reduce target weight to ~1.5% of portfolio (half of benchmark healthcare allocation). Maximum remaining position: 2% of portfolio until technical confirmation. Avoid margin or leveraged exposure given binary catalysts ahead.